Using the osteoporosis self-assessment tool for referring older men for bone densitometry: A decision analysis

Journal of the American Geriatrics Society

Volumn 57, Issue 2, 2009, Pages 218-224

  Ito, Kouta ^a,b   Hollenberg, James P ^c   Charlson, Mary E ^c  

^a Memorial Sloan Kettering Cancer Center ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cost effectiveness analysis; OST; Osteoporosis; Screening

Indexed keywords

ALENDRONIC ACID;

AGED; ARTICLE; BONE DENSITOMETRY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT REFERRAL; QUALITY ADJUSTED LIFE YEAR; SELF EVALUATION;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE AND BONES; COST-BENEFIT ANALYSIS; DENSITOMETRY; HUMANS; MALE; MARKOV CHAINS; OSTEOPOROSIS; SELF ASSESSMENT (PSYCHOLOGY); SENSITIVITY AND SPECIFICITY;

EID: 58849158775     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2008.02110.x     Document Type: Article

References (50)

1. Looker AC, Orwoll ES, Johnston CC Jr. et al. Prevalence of low femoral bone density in older US adults from the NHANES III. J Bone Miner Res 1997 12 : 1761 1768.
2. Burge R, Dawson-Hughes B, Solomon DH et al. Incidence and economic burden of osteoporosis-related fracture in the United States, 2005-2025. J Bone Miner Res 2007 22 : 465 475.
3. Feldstein AC, Nichols G, Orwoll E et al. The near absence of osteoporosis treatment in patients with fractures. Osteoporosis Int 2005 16 : 953 962.
4. Dawson-Hughes B, Tosteson AN, Melton LJ III. Implications for absolute fracture risk assessment for osteoporosis guidelines in the USA. Osteoporosis Int 2008 19 : 449 458.
5. Qaseem A, Snow V, Shekelle P et al. Screening for osteoporosis in men: A systematic review for an American college of physicians guideline. Ann Intern Med 2008 148 : 685 701.
6. Anthropometric Reference Data for Children and Adults: U.S. Population, 1999-2002 [on-line]. Available at Accessed July 11, 2008.
7. Rud B, Hilden J, Hydstrup L et al. Performance of the osteoporosis self-assessment tool in ruling out low bone mineral density in postmenopausal women: A systematic review. Osteoporosis Int 2007 18 : 1177 1187.
8. Adler RA, Mongthuong TT, Petkov VI. Performance of the Osteoporosis Self-Assessment Tool for osteoporosis in American men. Mayo Clin Proc 2003 78 : 723 728.
9. Looker AC, Wahner HW, Dunn WL et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis Int 1998 8 : 468 490.
10. Ferrar L, Jiang G, Cawthon PM et al. Identification of vertebral fracture and non-osteoporotic short vertebral height in men: The MrOS study. J Bone Miner Res 2007 22 : 1434 1441.
11. Kanis JA, Johnell O, Oden A et al. The risk and burden of vertebral fractures in Sweden. Osteoporosis Int 2004 15 : 20 26.
12. Melton LJ III., Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: Comparison of urban with rural rates and changes in urban rates over time. Osteoporosis Int 1999 9 : 29 37.
13. Black DM, Palermo L, Grima DT. Developing better economic models for osteoporosis: Considerations for the calculation of the relative risk of fracture. Value Health 2006 9 : 54 58.
14. Johnell O, Kanis JA, Oden A et al. A predictive value of BMD for hip and other fractures. J Bone Miner Res 2005 20 : 1185 1194.
15. Kanis JA, Johnell O, De Laet C et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004 35 : 375 382.
16. De Laet C, Kanis JA, Odén A et al. Body mass index as a predictor of fracture: A meta-analysis. Osteoporosis Int 2005 16 : 1330 1338.
17. Sawka AM, Papaioannou A, Adachi JD et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Muscloskelet Disord 2005 6 : 39.
18. Kothawala P, Badamgarav E, Ryu S et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007 82 : 1493 1501.
19. Black DM, Cummings SR, Karpf DB et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 348 : 1535 1541.
20. United States Life Tables, 2003 [on-line]. Available at Accessed July 11, 2008.
21. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality, and costs. J Am Geriatr Soc 2003 51 : 364 370.
22. Calle EE, Thun MJ, Petrelli JM et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Eng J Med 1999 341 : 1097 1105.
23. Office of Technology Assessment Hip Fracture Outcomes in People Age 50 and Over - Background Paper. U.S. Congress. 1994, OTA-BP-H-120.
24. Manton KG. A longitudinal study of functional changes and mortality in the United States. J Gerontol 1988 43 : S153 S161.
25. Chrischilles EA, Butler D, Davis CS et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991 151 : 2026 2032.
26. Hanmer J, Lawrence WF, Anderson JP et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006 26 : 391 400.
27. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis Int 2002 13 : 768 776.
28. US Consumer Price Index for Medical Care for All Urban Consumers [on-line]. Available at Accessed July 11, 2008.
29. Gabriel SE, Tosteson AN, Leibson CL et al. Direct medical costs attributable to osteoporotic fractures. Osteoporosis Int 2002 13 : 323 330.
30. Harrow BS, Tennstedt SL, Mckinlay JB. How costly is it to care for disabled elders in a community setting? Gerontologist 1995 35 : 808 813.
31. GE Financial Nursing Home Cost of Care Survey. Richmond, VA : GE Financial Assurance Holdings, Inc., 2003.
32. Centers for Medicare and Medicaid Services. Physician Fee Schedule Search: 2007 [on-line]. Available at Accessed July 11, 2008.
33. Available at Accessed July 11, 2008.
34. Melton LJ III., Chrischilles EA, Cooper C et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992 7 : 1005 1010.
35. Schousboe JT, Taylor BC, Fink HA et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007 298 : 629 637.
36. Barrett JA, Baron JA, Karagas MA et al. Fracture risk in the U.S. Medicare population. J Clin Epidemiol 1999 52 : 243 249.
37. Schousboe JT, Ensrud KE, Nyman JA et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005 53 : 1697 1704.
38. Mobley LR, Hoerger TJ, Witternborn JS et al. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 2006 26 : 194 206.
39. Pignone M, Saha S, Hoerger T. Cost-effective analyses of colorectal cancer screening. A systematic review for the U.S. Preventive Services Tasks Force. Ann Intern Med 2002 137 : 96 104.
40. Mandelblatt J, Saha S, Teutsch S et al. The cost-effectiveness of screening mammography beyond age 65 years. A systematic review for the U.S. Preventive Services Tasks Force. Ann Intern Med 2003 139 : 835 842.
41. Coley CM, Barry MJ, Fleming C. Clinical guidelines: Part II: Early detection of prostate cancer: Part II. Estimating the risks, benefits, and costs. Ann Intern Med 1997 126 : 468 479.
42. Cranney A, Wells G, Willan A et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002 23 : 508 516.
43. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporosis Int 2007 18 : 1481 1491.
44. Tosteson AN, Rosenthal DI, Melton LJ III et al. Cost effectiveness of screening perimenopausal women for osteoporosis: Bone densitometry and hormone replacement therapy. Ann Intern Med 1990 113 : 594 603.
45. Office of Technology Assessment. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. U.S. Government Printing Office. 1995
46. Brown MA, Bradlow J, Gray AM. Cost-effectiveness of bone density measurements. J Br Menopause Soc 2001 7 : 130 135.
47. Nagata-Kobayashi S, Shimbo T, Fukui T. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Res 2002 20 : 350 357.
48. Schott AM, Ganne C, Hans D et al. Which screening strategy using BMD measurements would be most cost-effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporosis Int 2007 18 : 143 151.
49. NIH Consensus Development and the State of the Science Conferences. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001 285 : 785 795.
50. Gourlay SM, Miller WC, Richy F et al. Performance of osteoporosis risk assessment tools in postmenopausal women aged 54-64 years. Osteoporosis Int 2005 16 : 921 927.